HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract researchHYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research

Sai Life Sciences to Recruit 700+ Professionals in FY27

2026/02/20 17:15
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen crypto.news@mexc.com üzerinden bizimle iletişime geçin.

HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.

The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others.

A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “We are at an inflection point for the Indian CRDMO industry. Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale — with the right infrastructure, strong digital and quality systems, and deep scientific capability.”

Krishna added, “For scientists, this is a genuinely exciting moment. They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here—without compromising on scientific rigor, exposure, or the quality of work.”

The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up.

As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.

Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. The majority of new roles will be based in Hyderabad, home to the company’s largest integrated R&D campus. With more than 3,400 scientists and professionals currently on board, the planned hiring reflects its continued growth and its expanding role as a global CRDMO partner.

About Sai Life Sciences

Sai Life Sciences is a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules. With operations across India, the UK, and the US, Sai Life Sciences offers scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. www.sailife.com

Contacts

For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communications
Sai Life Sciences  
Ph: +91 9121295355
sriram.g@sailife.com

Piyasa Fırsatı
Sharpe AI Logosu
Sharpe AI Fiyatı(SAI)
$0.000964
$0.000964$0.000964
+2.55%
USD
Sharpe AI (SAI) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen crypto.news@mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

StrictlyVC San Francisco Unveils Electrifying Speaker Lineup with TDK Ventures and Replit Leaders

StrictlyVC San Francisco Unveils Electrifying Speaker Lineup with TDK Ventures and Replit Leaders

BitcoinWorld StrictlyVC San Francisco Unveils Electrifying Speaker Lineup with TDK Ventures and Replit Leaders The venture capital landscape prepares for a significant
Paylaş
bitcoinworld2026/04/02 04:20
Next Crypto to $1: APEMARS 100X Presale Gains as Hedera and Tron Face Volatility

Next Crypto to $1: APEMARS 100X Presale Gains as Hedera and Tron Face Volatility

Crypto markets are acting like a meme coin that just discovered espresso, fast moves, sharp reversals, and plenty of confusion. One minute, traders are celebrating
Paylaş
Techbullion2026/04/02 04:15
Trump Approval Rating Tracker: 39% In Latest Survey

Trump Approval Rating Tracker: 39% In Latest Survey

The post Trump Approval Rating Tracker: 39% In Latest Survey appeared on BitcoinEthereumNews.com. Sept. 16-18 net approval rating: Trump’s favorability rating declined three points to 39% and the share of U.S. adults who have an unfavorable view of him increased two points to 57% compared to last week in an Economist/YouGov survey of 1,567 U.S. adults conducted Sept. 12-15 (margin of error 3.6). The results represent an 11-point decline in Trump’s 50% favorability rating at the start of his term, according to Economist/YouGov polling. Sept. 15-6 net approval rating: Trump’s job performance improved one point, to 46%, in Morning Consult’s weekly survey compared to the previous week, while his disapproval rating stayed stagnant at 52% (the poll of 2,204 registered U.S. voters was conducted Sept. 12-14 and has a margin of error of 2). The poll found the killing of conservative activist Charlie Kirk is the top story of 2025, with 67% of voters saying they’ve seen, read or heart “a lot” about it, according to Morning Consult, well above hundreds of other news events Morning Consult has asked about this year. Sept. 10-14: On par with two other polls this week, Trump had a 42% approval rating in the latest Reuters/Ipsos survey conducted Sept. 5-9, while 56% disapproved, representing a two-point increase from the groups’ August poll in his disapproval rating and a two-point uptick in his approval rating (the poll of 1,084 U.S. adults has a margin of error of 3). Sept. 8-7: Trump’s approval rating declined one point from last week, to 45%, tied with his record low since taking office, according to Morning Consult’s weekly survey that found 52% disapprove of his job performance (the poll of 2,201 registered voters conducted Sept. 6-8 has a margin of error of 2). Sept. 7-12: Trump’s approval rating ticked up two points from July, to 44%, while his disapproval rating declined two…
Paylaş
BitcoinEthereumNews2025/09/18 01:08

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity